Get the Stockscreener App
1.08
2.70%
-0.03
After Hours:
1.10
0.02
+1.85%
Renovorx Inc stock is traded at $1.08, with a volume of 489.76K.
It is down -2.70% in the last 24 hours and down -15.62% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$1.11
Open:
$1.15
24h Volume:
489.76K
Relative Volume:
1.03
Market Cap:
$39.58M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-1.8947
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
-19.40%
1M Performance:
-15.62%
6M Performance:
+39.90%
1Y Performance:
+10.20%
1-Day Range:
$1.07
$1.15
1-Week Range:
$1.05
$1.41
52-Week Range:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.08 | 40.68M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Renovorx Inc Stock (RNXT) Latest News
RenovoRx : Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD - MarketScreener
Is RenovoRx Inc. reversing from oversold territoryJuly 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Is RenovoRx Inc. stock entering bullish territoryPortfolio Return Summary & Safe Entry Momentum Tips - newser.com
Identifying reversal signals in RenovoRx Inc.Weekly Investment Report & Free Growth Oriented Trading Recommendations - newser.com
RenovoRx Inc. stock chart pattern explainedMarket Weekly Review & Step-by-Step Trade Execution Guides - newser.com
Relative strength of RenovoRx Inc. in sector analysisJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
What does recent volatility data suggest for RenovoRx Inc.Trade Entry Summary & Breakout Confirmation Trade Signals - newser.com
Is RenovoRx Inc. forming a bottoming baseEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
Will RenovoRx Inc. stock outperform Dow Jones indexAnalyst Upgrade & Risk Controlled Daily Trade Plans - newser.com
RenovoRx adds interventional oncology expert to scientific advisory board By Investing.com - Investing.com Nigeria
RenovoRx’s Earnings Call: Positive Outlook Amid Growth - MSN
RenovoRx adds interventional oncology expert to scientific advisory board - Investing.com
RenovoRx Appoints Renowned Oncologist Thierry de Baère, MD, PhD, to Scientific Advisory Board - Quiver Quantitative
400+ publications & 22,000 citations: RenovoRx appoints Thierry de Baère to Scientific Advisory Board - Stock Titan
Will RenovoRx Inc. outperform the marketMarket Weekly Review & Intraday High Probability Setup Alerts - newser.com
Will earnings trigger a reversal in RenovoRx Inc.Buy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
Forecasting RenovoRx Inc. price range with options data2025 Investor Takeaways & Weekly Momentum Picks - newser.com
Is RenovoRx Inc. stock reversal real or fake2025 Short Interest & Real-Time Volume Triggers - newser.com
RenovoRx : Corporate Overview - MarketScreener
Custom strategy builders for tracking RenovoRx Inc.2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
Developing predictive dashboards with RenovoRx Inc. dataEarnings Overview Report & Long-Term Growth Portfolio Plans - newser.com
How institutional ownership impacts RenovoRx Inc. stock2025 Short Interest & Fast Gaining Stock Reports - newser.com
RenovoRx prices public offering to raise $12.1M - MSN
Comparing Annovis Bio (NYSE:ANVS) & RenovoRx (NASDAQ:RNXT) - Defense World
RenovoRx (NASDAQ:RNXT) Trading Up 7.6% – Here’s What Happened - Defense World
What analysts say about RenovoRx Inc stockCurrency Fluctuation Impact & Register for the Next Free Workshop - earlytimes.in
RenovoRx Inc Stock Analysis and ForecastTechnical Pattern Recognition & Budget Friendly Portfolio Growth - earlytimes.in
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Renovorx Inc Stock (RNXT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bagai Shaun | Chief Executive Officer |
Aug 25 '25 |
Buy |
0.91 |
5,000 |
4,549 |
330,040 |
| Agah Ramtin | Chief Medical Officer |
Jun 05 '25 |
Buy |
1.40 |
21,000 |
29,400 |
734,460 |
| Marton Laurence | Director |
May 02 '25 |
Option Exercise |
0.15 |
20,480 |
3,072 |
66,164 |
| Agah Ramtin | Chief Medical Officer |
Apr 15 '25 |
Buy |
0.90 |
15,000 |
13,500 |
1,113,460 |
| Bagai Shaun | Chief Executive Officer |
Apr 15 '25 |
Buy |
0.91 |
7,500 |
6,821 |
320,040 |
| Agah Ramtin | Chief Medical Officer |
Apr 11 '25 |
Buy |
0.80 |
20,000 |
16,000 |
1,098,460 |
| Kocak Ron | VP Controller and PAO |
Apr 10 '25 |
Buy |
0.79 |
6,500 |
5,135 |
12,595 |
| Kocak Ron | VP Controller and PAO |
Apr 09 '25 |
Buy |
0.80 |
6,000 |
4,800 |
6,095 |
| Kocak Ron | VP Controller and PAO |
Apr 08 '25 |
Buy |
0.80 |
95 |
76 |
95 |
| Agah Ramtin | Chief Medical Officer |
Apr 09 '25 |
Buy |
0.81 |
30,000 |
24,399 |
1,078,460 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):